Dubai - Sharikat Mubasher: The pioneering biotech company, BioSapien, announced a new extension of its pre-series A funding round to reach over $8 million, with participation from Globivest and several investors, including Global Ventures, Golden Gate Ventures, and Dara Holdings.  

In a statement today, the company announced the appointment of Joseph Borrello as Chief Technology Officer, Sonia Ramamoorthy as Head of Medical Affairs, Agnes Westelinck as Head of Regulatory U.S., Dirk Richter as Head of Regulatory U.A.E., David Briere as Director of Pharmacology, and Jerry Webb BSc as Head of Quality, in addition to other new hires across all tiers of the company.

Commenting on these milestones, Khatija Ali, CEO of BioSapien, said: “I am delighted to announce an extension of BioSapien’s pre-Series A funding round. As a female-led healthcare fund in the MENA region - and backed by EU pharma - we are proud to have Globivest as an investor and strategic partner.”

She affirmed that the new hires will enable the company to shape a future where precision medicine is both globally impactful and locally accessible.

For her part, Laura-Joy Boulos, Partner at Globivest, commented: “At Globivest, we back companies that don’t just promise innovation - they deliver transformative, science-backed solutions with the power to shift paradigms. BioSapien’s MediChip™ platform is a breakthrough in localized cancer treatment - scalable, precise, and deeply aligned with our One Health mission. We’re proud to support Dr. Khatija Ali and her team as they build the future of accessible precision medicine.”

MediChip is BioSapien’s revolutionary localized cancer treatment platform. This flagship technology enables sustained, targeted release of chemotherapeutics directly at the tumor site, minimizing systemic toxicity and revolutionizing cancer care.